AHMUi001-A
General
Cell Line |
|
hPSCreg name | AHMUi001-A |
Cite as: | AHMUi001-A (RRID:CVCL_C1SF) |
Cell line type | Human induced pluripotent stem cell (hiPSC) |
Similar lines |
FINCBi006-A (mt1108 clone #121, mt1108 #121) Donor's gene variants: MT-ND6, MT-ND6, MT-ND4L, MT-ND4L Donor diseases: Leber hereditary optic neuropathy FINCBi005-A (mt1072 clone #103, mt1072 #103) Donor's gene variants: MT-ND6, MT-ND6, MT-ND4L, MT-ND4L Donor diseases: Leber hereditary optic neuropathy FINCBi001-A (F56Lcl33, F56L 33M) Donor's gene variants: MT-ND1, MT-ND1 Donor diseases: Leber hereditary optic neuropathy REGUi009-A (myasthenic syndrome due to mutation in ColQ, hiPS 5-9016) Donor diseases: Congenital Myasthenic Syndrome |
Last update | 15th August 2022 |
User feedback | |
Provider |
|
Generator |
dongmei ji (AHMU)
Contact:
dongmei ji (AHMU) |
Owner | dongmei ji (AHMU) |
Distributors | |
Derivation country | China |
External Databases |
|
BioSamples | SAMEA110176023 |
Cellosaurus | CVCL_C1SF |
Wikidata | Q114310539 |
General Information |
|
Publications | |
* Is the cell line readily obtainable for third parties? |
No |
Donor Information
General Donor Information |
|
Sex | male |
Ethnicity | Asian (China) |
Phenotype and Disease related information (Donor) |
|
Diseases | A disease was diagnosed.
|
Disease associated phenotypes |
|
Non-disease associated phenotypes |
|
Family history | The proband was suffered from hereditary optic neuropathy. The proband's grandmother, Mother, sister and uncle all have mitochondria 3635G>A mutation. Theproband's grandmother, both uncles have clinical manifestation. |
Is the medical history available upon request? | The proband was suffered from hereditary optic neuropathy when he was child. |
Is clinical information available? | The probandharbours homoplasmic m.3635G>A mutations and has clinical symptoms. |
Karyotyping (Donor) |
|
Has the donor karyotype been analysed? |
Yes
46,XY
|
Other Genotyping (Donor) |
|
Is there genome-wide genotyping or functional data available? |
No
|
External Databases (Donor) |
|
BioSamples | SAMEA110176024 |
Ethics
Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
Was the consent voluntarily given? | Yes |
Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
Can you provide us with a copy of the Donor Information Sheet provided to the donor? | No |
Please provide contact information of the holder of the original Donor Information Sheet. | Holder:Dongmei Ji,Tel:008615155158242 |
Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes |
Alternatives to consent are available? | No |
Confirm that consent was obtained by a qualified professional | Yes |
Has the donor been informed about how her/his data will be protected? | Yes |
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | anonymised |
Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
Does consent permit unforeseen future research, without further consent? | No |
Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? | No |
Does consent expressly prevent development of commercial products? | Yes |
Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? | Yes |
Does consent expressly permit storage of donated embryo/tissue for an unlimited time? | Yes |
Does consent expressly permit storage of cells derived from the donated embryo/tissue for an unlimited time? | Yes |
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
How may genetic information associated with the cell line be accessed? | Controlled Access |
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
Name of accrediting authority involved? | the Ethics Committee of the Anhui Medical University (Hefei, China; Approval No. 20190190). |
Approval number | Approval No. 20190190 |
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
Source cell type |
Mononuclear cells collected from peripheral blood.
Synonyms
|
Source cell origin |
A liquid tissue; its major function is to transport oxygen throughout the body. It also supplies the tissues with nutrients, removes waste products, and contains various components of the immune system defending the body against infection. Several hormones also travel in the blood.
Synonyms
|
Passage number reprogrammed | 6 |
Reprogramming method |
|
Vector type | Integrating |
Vector | Plasmid |
Genes | |
Is the used vector excisable? |
Unknown |
Absence of reprogramming vector(s)? |
Unknown |
Reprogramming vectors silenced? | |
Methods used |
RT-PCR
|
Vector free reprogramming |
|
Other |
|
Derived under xeno-free conditions |
Unknown |
Derived under GMP? |
Unknown |
Available as clinical grade? |
Unknown |
Culture Conditions
Surface coating | Matrigel/Geltrex |
Medium |
Other medium:
Base medium:
Main protein source: Serum concentration: % |
Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | Yes |
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
Marker | Present | Absent |
mCpG | ||
OCT4 | X |
Morphology pictures
Differentiation Potency
Genotyping
Karyotyping (Cell Line) |
|
Has the cell line karyotype been analysed? |
Yes
|
Other Genotyping (Cell Line) |
Login to share your feedback, experiences or results with the research community.